European regulator issues positive opinion on lung drug Daxas

04/26/2010 | Wall Street Journal, The

The European Medicines Agency backed Nycomed and Forest Laboratories' application to market lung drug Daxas as maintenance treatment for chronic bronchitis patients with severe chronic obstructive pulmonary disease. European approval would make Daxas the first oral drug in the region for the life-threatening condition.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC